Search research articles
Contact Us
Filters
Showing results (151-160 of 282) with videos related to
Page
of 29
Sort By:
The Science of the Total Environment
|
May 1, 2012
Estimations of historical atmospheric mercury concentrations from mercury refining and present-day soil concentrations of total mercury in Huancavelica, Peru
Nicholas A Robins, Nicole Hagan, Susan Halabi, et al.
The New England Journal of Medicine
|
March 7, 2003
A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer
Robert S Sandler, Susan Halabi, John A Baron, et al.
The Prostate
|
September 10, 2019
Phase 1b trial of docetaxel, prednisone, and pazopanib in men with metastatic castration-resistant prostate cancer
Daniel J George, Susan Halabi, Patrick Healy, et al.
Future Oncology (London, England)
|
June 18, 2024
End points in clinical trials in diffuse large B-cell lymphoma: time for more dialogue?
Evgeny Degtyarev, Natacha Bolaños, Joshua D Brody, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 29, 2012
Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401
William Kevin Kelly, Susan Halabi, Michael Carducci, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 15, 2023
Randomized Phase II Multicenter Trial of Abiraterone Acetate With or Without Cabazitaxel in the Treatment of Metastatic Castration-Resistant Prostate Cancer
Susan F Slovin, Karen Knudsen, Susan Halabi, et al.
Cancer
|
August 6, 2013
The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) (Alliance)
Rahul Aggarwal, Susan Halabi, William Kevin Kelly, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 22, 2008
Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206
Brian I Rini, Susan Halabi, Jonathan E Rosenberg, et al.
Prostate Cancer and Prostatic Diseases
|
February 12, 2024
Prognostic and predictive analyses of circulating plasma biomarkers in men with metastatic castration resistant prostate cancer treated with docetaxel/prednisone with or without bevacizumab
Andrew B Nixon, Yingmiao Liu, Qian Yang, et al.
International Journal of Radiation Oncology, Biology, Physics
|
December 1, 2020
Combination of Radiation Therapy and Short-Term Androgen Blockade With Abiraterone Acetate Plus Prednisone for Men With High- and Intermediate-Risk Localized Prostate Cancer
Bridget F Koontz, Karen E Hoffman, Susan Halabi, et al.
Page
of 29
Search research articles
Search
Showing results (151-160 of 282) with videos related to
Sort By:
Page
of 29
The Science of the Total Environment
|
May 1, 2012
Estimations of historical atmospheric mercury concentrations from mercury refining and present-day soil concentrations of total mercury in Huancavelica, Peru
Nicholas A Robins, Nicole Hagan, Susan Halabi, et al.
The New England Journal of Medicine
|
March 7, 2003
A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer
Robert S Sandler, Susan Halabi, John A Baron, et al.
The Prostate
|
September 10, 2019
Phase 1b trial of docetaxel, prednisone, and pazopanib in men with metastatic castration-resistant prostate cancer
Daniel J George, Susan Halabi, Patrick Healy, et al.
Future Oncology (London, England)
|
June 18, 2024
End points in clinical trials in diffuse large B-cell lymphoma: time for more dialogue?
Evgeny Degtyarev, Natacha Bolaños, Joshua D Brody, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 29, 2012
Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401
William Kevin Kelly, Susan Halabi, Michael Carducci, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 15, 2023
Randomized Phase II Multicenter Trial of Abiraterone Acetate With or Without Cabazitaxel in the Treatment of Metastatic Castration-Resistant Prostate Cancer
Susan F Slovin, Karen Knudsen, Susan Halabi, et al.
Cancer
|
August 6, 2013
The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) (Alliance)
Rahul Aggarwal, Susan Halabi, William Kevin Kelly, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 22, 2008
Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206
Brian I Rini, Susan Halabi, Jonathan E Rosenberg, et al.
Prostate Cancer and Prostatic Diseases
|
February 12, 2024
Prognostic and predictive analyses of circulating plasma biomarkers in men with metastatic castration resistant prostate cancer treated with docetaxel/prednisone with or without bevacizumab
Andrew B Nixon, Yingmiao Liu, Qian Yang, et al.
International Journal of Radiation Oncology, Biology, Physics
|
December 1, 2020
Combination of Radiation Therapy and Short-Term Androgen Blockade With Abiraterone Acetate Plus Prednisone for Men With High- and Intermediate-Risk Localized Prostate Cancer
Bridget F Koontz, Karen E Hoffman, Susan Halabi, et al.
Page
of 29